French pharmaceutical Sanofi-Aventis SA (SAN.FR) Monday said it secured control of U.S. biotech firm Genzyme Corp. (GENZ) after a tender offer that expired on Friday.

Sanofi-Aventis has secured about 84.6% of Genzyme's outstanding shares and about 77% of the shares in a fully diluted basis.

The French company announced a new tender offer starting Monday and ending Thursday at 6 p.m. New York time to give remaining Genzyme shareholders the opportunity to tender their shares.

-By Inti Landauro, Dow Jones Newswires; +33 1 4017 1740; inti.landauro@dowjones.com
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Genzyme Charts.
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Genzyme Charts.